RxSight (RXST)

• Market cap: $1.36B
• 1 day: -11.86%
• 5 days: -10.02%
• 1 month: -24.88%
• 3 months: -36.47%
• 6 months: -39.85%
• Year to date: -8.16%
• 1 year: -11.77%
• 5 years: 110.37%
• 10 years: 110.37%
• Sector: Healthcare
• Industry: Ophthalmic Goods

About: RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The Company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.

Employees: 374

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

1,355% more call options, than puts

Call options by funds: $23.1M | Put options by funds: $1.59M

36% more repeat investments, than reductions

Existing positions increased: 87 | Existing positions reduced: 64

6.33% less ownership

Funds ownership: 91.82% [Q2] → 85.49% (-6.33%) [Q3]

7% less funds holding

Funds holding: 227 [Q2] → 211 (-16) [Q3]

22% less capital invested

Capital invested by funds: $2.15B [Q2] → $1.68B (-$477M) [Q3]

33% less first-time investments, than exits

New positions opened: 33 | Existing positions closed: 49

71% less funds holding in top 10

Funds holding in top 10: 7 [Q2] → 2 (-5) [Q3]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $40 19% upside
• Avg. target: $52 53% upside
• High target: $72 114% upside

4 analyst ratings

• positive: 2 50%
• neutral: 2 50%
• negative: 0 0%

Stifel Thomas Stephan 31% 1-year accuracy 5 / 16 met price target	19% upside $40	Hold Downgraded	20 Dec 2024
Wells Fargo Larry Biegelsen 51% 1-year accuracy 24 / 47 met price target	25% upside $42	Equal-Weight Downgraded	11 Dec 2024
UBS Danielle Antalffy 38% 1-year accuracy 5 / 13 met price target	54% upside $52	Buy Initiated	6 Dec 2024
Jefferies Young Li 50% 1-year accuracy 1 / 2 met price target	114% upside $72	Buy Initiated	29 Oct 2024